多发性骨髓瘤
免疫学
骨髓
癌症研究
免疫系统
医学
免疫疗法
干细胞
CD8型
生物
遗传学
作者
Simone A. Minnie,Olivia G. Waltner,Kathleen S. Ensbey,Nicole S Nemychenkov,Christine R. Schmidt,Shruti S. Bhise,Samuel R.W. Legg,Gabriela Campoy,Luke Samson,Rachel D. Kuns,Ting Zhou,John D. Huck,Slavica Vučković,Danniel Zamora,Albert C. Yeh,Andrew Spencer,Motoko Koyama,Kate A. Markey,Steven Lane,Michael Boeckh
出处
期刊:Science immunology
[American Association for the Advancement of Science]
日期:2022-10-14
卷期号:7 (76)
被引量:17
标识
DOI:10.1126/sciimmunol.abo3420
摘要
Some hematological malignancies such as multiple myeloma are inherently resistant to immune-mediated antitumor responses, the cause of which remains unknown. Allogeneic bone marrow transplantation (alloBMT) is the only curative immunotherapy for hematological malignancies due to profound graft-versus-tumor (GVT) effects, but relapse remains the major cause of death. We developed murine models of alloBMT where the hematological malignancy is either sensitive [acute myeloid leukemia (AML)] or resistant (myeloma) to GVT effects. We found that CD8
科研通智能强力驱动
Strongly Powered by AbleSci AI